These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 25977345)

  • 41. Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.
    Lu SX; Kappel LW; Charbonneau-Allard AM; Atallah R; Holland AM; Turbide C; Hubbard VM; Rotolo JA; Smith M; Suh D; King C; Rao UK; Yim N; Bautista JL; Jenq RR; Penack O; Na IK; Liu C; Murphy G; Alpdogan O; Blumberg RS; Macian F; Holmes KV; Beauchemin N; van den Brink MR
    PLoS One; 2011; 6(7):e21611. PubMed ID: 21760897
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differential effects of itacitinib, fedratinib, and ruxolitinib in mouse models of hemophagocytic lymphohistiocytosis.
    Keenan C; Albeituni S; Oak N; Stroh A; Tillman HS; Wang Y; Freeman BB; Alemán-Arteaga S; Meyer LK; Woods R; Verbist KC; Zhou Y; Cheng C; Nichols KE
    Blood; 2024 Jun; 143(23):2386-2400. PubMed ID: 38446698
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Solid Tumor-Induced Immune Regulation Alters the GvHD/GvT Paradigm after Allogenic Bone Marrow Transplantation.
    Dang N; Lin Y; Rutgeerts O; Sagaert X; Billiau AD; Waer M; Sprangers B
    Cancer Res; 2019 May; 79(10):2709-2721. PubMed ID: 30936086
    [TBL] [Abstract][Full Text] [Related]  

  • 44. JAK1/2 inhibition impairs the development and function of inflammatory dendritic epidermal cells in atopic dermatitis.
    Klaeschen AS; Nümm TJ; Herrmann N; Leib N; Maintz L; Sakai T; Wenzel J; Bieber T
    J Allergy Clin Immunol; 2021 Jun; 147(6):2202-2212.e8. PubMed ID: 33338537
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases.
    Covington M; He X; Scuron M; Li J; Collins R; Juvekar A; Shin N; Favata M; Gallagher K; Sarah S; Xue CB; Peel M; Burke K; Oliver J; Fay B; Yao W; Huang T; Scherle P; Diamond S; Newton R; Zhang Y; Smith P
    Eur J Pharmacol; 2020 Oct; 885():173505. PubMed ID: 32861662
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release.
    Hermans MAW; Schrijver B; van Holten-Neelen CCPA; Gerth van Wijk R; van Hagen PM; van Daele PLA; Dik WA
    Clin Exp Allergy; 2018 Nov; 48(11):1412-1420. PubMed ID: 29939445
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function.
    Betts BC; Veerapathran A; Pidala J; Yang H; Horna P; Walton K; Cubitt CL; Gunawan S; Lawrence HR; Lawrence NJ; Sebti SM; Anasetti C
    Sci Transl Med; 2017 Jan; 9(372):. PubMed ID: 28077684
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model.
    Ito M; Shizuru JA
    Biol Blood Marrow Transplant; 1999; 5(6):357-68. PubMed ID: 10595813
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro.
    Murakami K; Kobayashi Y; Uehara S; Suzuki T; Koide M; Yamashita T; Nakamura M; Takahashi N; Kato H; Udagawa N; Nakamura Y
    PLoS One; 2017; 12(7):e0181126. PubMed ID: 28708884
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cellular tumor vaccines administered after T cell-depleted allogeneic bone marrow transplantation induce effective anti-tumor immune responses.
    Mundhada S; Shaw J; Mori S; Savary CA; Mullen CA
    Leuk Lymphoma; 2005 Apr; 46(4):571-80. PubMed ID: 16019486
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results.
    Pidala J; Walton K; Elmariah H; Kim J; Mishra A; Bejanyan N; Nishihori T; Khimani F; Perez L; Faramand RG; Davila ML; Nieder ML; Sagatys EM; Holtan SG; Lawrence NJ; Lawrence HR; Blazar BR; Anasetti C; Sebti SM; Betts BC
    Clin Cancer Res; 2021 May; 27(10):2712-2722. PubMed ID: 33753457
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The complex and central role of interferon-γ in graft-versus-host disease and graft-versus-tumor activity.
    Wang H; Yang YG
    Immunol Rev; 2014 Mar; 258(1):30-44. PubMed ID: 24517424
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.
    de Oliveira MB; Fook-Alves VL; Eugenio AIP; Fernando RC; Sanson LFG; de Carvalho MF; Braga WMT; Davies FE; Colleoni GWB
    Cancer Lett; 2017 Sep; 403():206-215. PubMed ID: 28645562
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Programming of donor T cells using allogeneic δ-like ligand 4-positive dendritic cells to reduce GVHD in mice.
    Mochizuki K; Meng L; Mochizuki I; Tong Q; He S; Liu Y; Purushe J; Fung H; Zaidi MR; Zhang Y; Reshef R; Blazar BR; Yagita H; Mineishi S; Zhang Y
    Blood; 2016 Jun; 127(25):3270-80. PubMed ID: 27143255
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comprehensive Analysis of the Activation and Proliferation Kinetics and Effector Functions of Human Lymphocytes, and Antigen Presentation Capacity of Antigen-Presenting Cells in Xenogeneic Graft-Versus-Host Disease.
    Kawasaki Y; Sato K; Hayakawa H; Takayama N; Nakano H; Ito R; Mashima K; Oh I; Minakata D; Yamasaki R; Morita K; Ashizawa M; Yamamoto C; Hatano K; Fujiwara SI; Ohmine K; Muroi K; Kanda Y
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1563-1574. PubMed ID: 29678638
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Modulation of allogeneic CD8+ T-cell response by DZNep controls GVHD while preserving hematopoietic chimerism.
    Wang J; Li L; Xu M; Rong R; Zhu T
    Transplantation; 2013 Nov; 96(9):774-81. PubMed ID: 23900211
    [TBL] [Abstract][Full Text] [Related]  

  • 57. IFN-γ receptor-deficient donor T cells mediate protection from graft-versus-host disease and preserve graft-versus-tumor responses after allogeneic bone marrow transplantation.
    Sun K; Hsiao HH; Li M; Ames E; Bouchlaka M; Welniak LA; Hagino T; Jagdeo J; Pai CC; Chen M; Blazar BR; Abedi M; Murphy WJ
    J Immunol; 2012 Aug; 189(4):2033-42. PubMed ID: 22778394
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cyclin-dependent kinase 5 activity is required for allogeneic T-cell responses after hematopoietic cell transplantation in mice.
    Askew D; Pareek TK; Eid S; Ganguly S; Tyler M; Huang AY; Letterio JJ; Cooke KR
    Blood; 2017 Jan; 129(2):246-256. PubMed ID: 28064242
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Role of Co-stimulatory/Co-inhibitory Signals in Graft-vs.-Host Disease.
    Kumar S; Leigh ND; Cao X
    Front Immunol; 2018; 9():3003. PubMed ID: 30627129
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.